"Breast Biopsy Market by Product (Needles, Tables, Assay Kit), by Type (Needle Biopsy (CNB, FNAB, VAB), Liquid Biopsy (CTC, ctDNA)), Guidance (Image-Guided (Mammography, Ultrasound, MRI), Liquid Biopsy (NGS, PCR, Microarray-based)) - Global Forecasts to 2025", published by MarketsandMarkets™, is projected to reach USD 1,094 million by 2025 from USD 725 million in 2020, at a CAGR of 8.6% during the forecast period.
Browse and in-depth TOC on "Breast
Biopsy
Market"
129 - Tables
37 - Figures
187 - Pages
Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=189011805
The
Technological advancements in the field of a breast biopsy and the rising
incidence of breast cancer are the major factors driving the growth of this
market. Additionally, the growing adoption of advanced techniques for breast
cancer screening and rising government and private investments for improving
breast cancer care are some of the other significant factors driving the growth
of this market.
The biopsy needles segment accounted for the largest
share of the market, by product, in 2019
Based on
the product, the Breast Biopsy Market is segmented into biopsy needles,
guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy
instruments, and other products. In 2019, the biopsy needles held significant
share of the market. The major share of this segment is primarily attributed to
the rising incidence of breast cancer and the growing breast cancer diagnosis
rate in developing countries. Moreover, rising preference to the minimally
invasive procedures and favorable reimbursement scenario in both developed as
well as developing countries will further drive the market growth.
Technological advancements to drive the growth of
NGS-based biopsy segment during the forecast period
Based on
guidance, the Breast Biopsy Market is segmented into image-guided biopsy and
liquid biopsy. The liquid biopsy segment is further divided into NGS-based,
PCR-based, and Microarray-based biopsy. Among these, the NGS-based biopsy
segment is expected to register significant growth over the forecast period.
Technological advancements and new product launches are other factors leading
to segment growth. Companies operating in the segment, such as Illumina, Inc.
(US), Thermo Fisher Scientific (US), and Fluxion Biosciences Inc. (US), are
focusing on high R&D investment to deliver novel and advanced platforms for
tumor diagnosis.
Needle biopsy segment is anticipated to hold major
share of the global Breast Biopsy Market in terms of type
Based on
type, the market is segmented into needle breast biopsy, open surgical breast
biopsy, and liquid breast biopsy. In 2019, the needle breast biopsy held a
major share of the market. Needle biopsy has replaced conventional excisional
biopsy as the standard diagnostic procedure for breast cancer. Rising adoption
of core needle biopsy by healthcare professionals due to advantages such as
high sensitivity and specificity and technological advancements are driving the
growth of the segment.
Get 10% Customization Research Report: - https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=189011805
North
America to hold a significant share of the Breast Biopsy Market
during the forecast period
The market
is segmented into five regional segments, namely, North America, Europe, Asia Pacific, Latin America,
and Middle
East & Africa. The North American region
accounted for the largest share of the market in 2019. The rising incidence of
breast cancer, easy accessibility and high adoption of advanced diagnostic
technologies (owing to the significant per capita annual healthcare expenditure
in the US and Canada),
presence of a favorable reimbursement scenario, and the rapidly increasing
geriatric population in the region are some of the major factors driving the
growth of the market in North
America.
The major
players operating in the Breast Biopsy
Market are Hologic, Inc. (US), Becton, Dickinson and Company (US),
Danaher Corporation (US), Merit Medical Systems (US), QIAGEN (Netherlands),
Biocept Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland),
Menarini Silicon Biosystems, Spa (Italy), Exact Sciences Corporation
(US), Illumina, Inc. (US), and Fluxion Biosciences Inc (US), among others.
About MarketsandMarkets™
MarketsandMarkets™
provides quantified B2B research on 30,000 high growth niche
opportunities/threats which will impact 70% to 80% of worldwide companies'
revenues. Currently servicing 7500 customers worldwide including 80% of global
Fortune 1000 companies as clients. Almost 75,000 top officers across eight
industries worldwide approach MarketsandMarkets™ for their painpoints around
revenues decisions.
Our 850
fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth
markets following the "Growth Engagement Model – GEM". The GEM aims
at proactive collaboration with the clients to identify new opportunities,
identify most important customers, write "Attack, avoid and defend"
strategies, identify sources of incremental revenues for both the company and
its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants
(Positioning top players across leaders, emerging companies, innovators,
strategic players) annually in high growth emerging segments.
MarketsandMarkets™ is determined to benefit more than 10,000 companies this
year for their revenue planning and help them take their
innovations/disruptions early to the market by providing them research ahead of
the curve.
MarketsandMarkets's
flagship competitive intelligence and market research platform,
"Knowledgestore" connects over 200,000 markets and entire value
chains for deeper understanding of the unmet insights along with market sizing
and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA:
1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/biopsy-devices-breast-biopsy-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/biopsy-devices-breast-biopsy.asp
No comments:
Post a Comment